Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

#4427

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Aim(s): To evaluate the efficacy and safety of SUR plus HAIC in later-line treatment of liver metastasis-dominated NEC.

Materials and methods: Pts with unresectable or metastatic NEC who have experienced disease progression or intolerance after first-line chemotherapy such as etoposide plus carboplatin/cisplatin were enrolled. Pts received SUR (250 mg orally, QD) combined with HAIC (mFOLFOX6 regimen). The primary endpoint is the PFS. The secondary endpoints are ORR, DCR, DoR, OS, and adverse reactions (AEs).

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,